Profound Medical Corp. – NASDAQ:PROF
Profound Medical Corp. stock price today
$4.58
-2.57
-35.94%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 18 hours
Profound Medical Corp. stock price monthly change
-22.87%
month
Profound Medical Corp. stock price quarterly change
-22.87%
quarter
Profound Medical Corp. stock price yearly change
-13.86%
year
Profound Medical Corp. key metrics
Market Cap | 173.49M |
Enterprise value | 169.64M |
P/E | -7.22 |
EV/Sales | 25.39 |
EV/EBITDA | -6.37 |
Price/Sales | 31.12 |
Price/Book | 3.99 |
PEG ratio | -1.09 |
EPS | -1.29 |
Revenue | 7.29M |
EBITDA | -28.29M |
Income | -28.24M |
Revenue Q/Q | 2.22% |
Revenue Y/Y | 1.65% |
Profit margin | -429.11% |
Oper. margin | -29.73% |
Gross margin | 45.22% |
EBIT margin | -29.73% |
EBITDA margin | -387.81% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeProfound Medical Corp. stock price history
Profound Medical Corp. stock forecast
Profound Medical Corp. financial statements
Average Price Target
$17
Potential upside: 271.17%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1.60M | -7.35M | -459.11% |
|---|---|---|---|
| Sep 2023 | 1.72M | -5.56M | -321.99% |
| Dec 2023 | 2.06M | -9.15M | -443.45% |
| Mar 2024 | 1.90M | -6.17M | -324.55% |
| Jun 2023 | 56806000 | 12.44M | 21.9% |
|---|---|---|---|
| Sep 2023 | 50444000 | 11.88M | 23.56% |
| Dec 2023 | 43686338 | 12.66M | 28.99% |
| Mar 2024 | 57322847 | 11.51M | 20.08% |
| Jun 2023 | -5.11M | 239K | -239K |
|---|---|---|---|
| Sep 2023 | -4.33M | 0 | -189K |
| Dec 2023 | -7.17M | 192.74K | -495.89K |
| Mar 2024 | -5.07M | 0 | 20.29M |
Profound Medical Corp. alternative data
| Aug 2023 | 131 |
|---|---|
| Sep 2023 | 131 |
| Oct 2023 | 131 |
| Nov 2023 | 131 |
| Dec 2023 | 131 |
| Jan 2024 | 131 |
| Feb 2024 | 131 |
| Mar 2024 | 131 |
| Apr 2024 | 131 |
| May 2024 | 131 |
| Jun 2024 | 131 |
| Jul 2024 | 131 |
Profound Medical Corp. other data
34.83%
-6.54%
of PROF is owned by hedge funds
7.25M
-1.21M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q1 2024 11 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 7 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 4 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Arun Swarup Menawat MBA, Ph.D. (1955) Chairman & Chief Executive Officer | $1,390,000 |
Mr. Aaron Davidson M.B.A., MBA (1968) Senior Vice President of Corporation Devel. | $233,220 |
Mr. Rashed Dewan (1968) Chief Accounting Officer, Vice President of Fin., Manufacturing & HR Operations | $173,100 |
Profound Medical: In Serious Trouble Despite Projected Growth
EDAP: Reiterate Buy After Multiple Investment Updates
Profound Medical: TULSA-PRO Now Selling, Recurring Revenues Up 43%
Profound Medical: Upsides Leading Into FY22 Earnings, Revise To Buy
Profound Medical Lacks Conviction To Overthrow Macro Headwinds
-
What's the price of Profound Medical Corp. stock today?
One share of Profound Medical Corp. stock can currently be purchased for approximately $4.58.
-
When is Profound Medical Corp.'s next earnings date?
Unfortunately, Profound Medical Corp.'s (PROF) next earnings date is currently unknown.
-
Does Profound Medical Corp. pay dividends?
No, Profound Medical Corp. does not pay dividends.
-
How much money does Profound Medical Corp. make?
Profound Medical Corp. has a market capitalization of 173.49M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 7.75% to 7.2M US dollars.
-
What is Profound Medical Corp.'s stock symbol?
Profound Medical Corp. is traded on the NASDAQ under the ticker symbol "PROF".
-
What is Profound Medical Corp.'s primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Profound Medical Corp.?
Shares of Profound Medical Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Profound Medical Corp.'s key executives?
Profound Medical Corp.'s management team includes the following people:
- Dr. Arun Swarup Menawat MBA, Ph.D. Chairman & Chief Executive Officer(age: 70, pay: $1,390,000)
- Mr. Aaron Davidson M.B.A., MBA Senior Vice President of Corporation Devel.(age: 57, pay: $233,220)
- Mr. Rashed Dewan Chief Accounting Officer, Vice President of Fin., Manufacturing & HR Operations(age: 57, pay: $173,100)
-
How many employees does Profound Medical Corp. have?
As Jul 2024, Profound Medical Corp. employs 131 workers.
-
When Profound Medical Corp. went public?
Profound Medical Corp. is publicly traded company for more then 5 years since IPO on 29 Oct 2019.
-
What is Profound Medical Corp.'s official website?
The official website for Profound Medical Corp. is profoundmedical.com.
-
Where are Profound Medical Corp.'s headquarters?
Profound Medical Corp. is headquartered at 2400 Skymark Avenue, Mississauga, ON.
-
How can i contact Profound Medical Corp.?
Profound Medical Corp.'s mailing address is 2400 Skymark Avenue, Mississauga, ON and company can be reached via phone at +1 647 476 1350.
-
What is Profound Medical Corp. stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Profound Medical Corp. in the last 12 months, the avarage price target is $17. The average price target represents a 271.17% change from the last price of $4.58.
Profound Medical Corp. company profile:
Profound Medical Corp.
profoundmedical.comExchange:
NASDAQ
Full time employees:
131
Industry:
Medical - Devices
Sector:
Healthcare
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
2400 Skymark Avenue
Mississauga, ON L4W 5K5
Mississauga, ON L4W 5K5
CIK: 0001628808
ISIN: CA74319B5027
CUSIP: 74319B502
